Bioelectric medicine could become a reality sooner than expected, thanks to an ambitious plan launched by GSK. We find out how nano-scale devices could harness the electrical language of the human body and explore the technology’s future potential.
Also in the latest issue of Pharma Technology Focus, we find out how the landmark decision in the US Supreme Court that DNA could not be patented will affect pharmaceutical research, explore the ethics of advertising drugs directly to the consumer in the light of a recent study and learn how manufacturers have used the a similar method for heavy metals testing for over a century.
Moreover, we ask whether certain barriers will hinder any further growth in the influenza market, investigate the often controversial decision-making process behind the approval or rejection of cancer treatments in the UK, and look at how virtual reality and e-learning could change science teaching and pharmaceutical training forever.
In this issue
Pharma Technology Focus Awards 2013: Ones to WatchIn recognition of outstanding pharmaceutical achievements over the past year, Pharmaceutical Technology Focus presents its Ones to Watch 2013.Click here to read more.
Body LanguageMedicines that speak the electrical language of the body could become a reality sooner rather than later, thanks to an ambitious plan launched by pharma giant GSK. Click here to read more.
DNA Patent LawEarlier this year the US Supreme Court made the landmark decision that DNA could not be patented. We ask what does this mean for DNA-based pharmaceutical research.Click here to read more.
The Ethics of TV AdvertisingThe US is one of only two countries in the world that allow big pharma to advertise prescription drugs directly to consumers. Pharma Technology Focus asks what happens when the language of advertising is applied to prescription medicines.Click here to read more.
Heavy Metals: Test at the LimitsIn 1905, the first heavy metals check in pharmaceuticals was introduced in the US. We learn how manufacturers are still using a similar method over a century later.Click here to read more.
Not To Be Sneezed AtWith the global influenza market expected to see substantial change in the next decade, research and consulting firm GlobalData asks whether certain barriers will hinder any further market growth.Click here to read more.
To Approve or Not ApproveDebate has raged in recent months over decisions to approve or not approve several cancer treatments in the UK. We ask at what point does life-saving medication no longer become cost worthy. Click here to read more.
Gaming for Virtual TrainingVirtual reality and e-learning could change science teaching and pharmaceutical training forever. Pharma Technology Focus meets the man behind recently released virtual laboratory Labster to find out how.Click here to read more.
Encouraging patients to enrol in clinical trials is no easy task and rates of participation vary widely. We explore innovative methods that are being applied to boost participation rates.
Also, we profile new developments in diabetes research, ask how a new open-source modelling application could help combat global outbreaks and consider whether 3D printing technology could be the next step in regenerative healing.
Moreover, we catch up with the latest developments in DARPA’s project Blue Angel, investigate a new model for monitoring and extracting intricate consumer-level data and look at how citizen research is contributing to the fight against cancer.
Subscribe for free to get each future issue of Pharma Technology Focus delivered directly to your inbox.
Digital Magazine FAQ
The digital magazine is viewable on any computer with Flash Player installed. It is also viewable on mobile devices, iPhones and iPads, although some features and videos may be disabled.